Clinical trials: Coronavirus 2019
COVID-19
Study to Evaluate the Effects of RO7496998 (AT-527) in Non-Hospitalized Adult and Adolescent Participants With Mild or Moderate COVID-19
This study will evaluate the efficacy, safety, antiviral activity, and pharmacokinetics of study drug RO7496998 (AT-527) compared to placebo in non-hospitalized adult and adolescent participants with mild to moderate coronavirus…
- Trial name
- MORNINGSKY (NCT04889040)
- Testing
- RO7496998
- Where
- 50 sites in Argentina, Belgium and 10 more
- Volunteers
- 216 people
- Sponsor
- Hoffmann-La Roche
Acute Lung Injury (ALI) Associated With COVID-19, Lung Inflammation Associated With COVID-19
TD-0903 for ALI Associated With COVID-19
This Phase 2 study will evaluate the efficacy, safety, pharmacodynamics and pharmacokinetics of inhaled TD-0903 compared with a matching placebo in combination with standard of care (SOC) in hospitalized patients with confirmed…
- Trial name
- NCT04402866
- Testing
- TD-0903
- Where
- 24 sites in United States, Brazil and 5 more
- Volunteers
- 235 people
- Sponsor
- Theravance Biopharma
Coronavirus Infection
NasoVAX in Patients With Early Coronavirus Infectious Disease 2019 (COVID-19)
The purpose of this study is to evaluate the safety and effectiveness of NasoVAX in preventing worsening of symptoms and hospitalization in patients with early COVID-19.
- Trial name
- NCT04442230
- Testing
- NasoVAX
- Where
- 7 sites in United States
- Volunteers
- 48 people
- Sponsor
- Altimmune, Inc.
Androgenetic Alopecia, Coronavirus Disease 2019
Association of Androgenetic Alopecia and Severity of Coronavirus Disease 2019 (COVID-19).
Coronavirus disease 2019 (COVID-19) can cause variable symptoms ranging from mild common cold-like symptoms to severe life threatening pneumonia.
- Conditions
- Androgenetic Alopecia, Coronavirus Disease 2019, Covid19, Male Pattern Baldness
- Trial name
- NCT04898166
- Where
- Pakistan
- Volunteers
- 300 people
- Sponsor
- Syeda Mahanum Ali
COVID-19
Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19
This is open-labe randomized multicenter comparative Phase III study conducted in 5 medical facilities. The objective of the study is to assess the efficacy and safety of Favipiravir compared with the Standard of care (SOC) in…
- Trial name
- NCT04542694
- Testing
- Favipiravir, Standard of care
- Where
- 5 sites in Russia
- Volunteers
- 200 people
- Sponsor
- Promomed, LLC
Antithrombin III Deficiency, Covid19
Antithrombin III in Infectious Disease Caused by COVID-19
The purpose of this research study is to see if participants who have SARS-CoV-2 and low levels of AT3 in the blood will benefit by being given AT3.
- Trial name
- NCT04899232
- Testing
- Antithrombin III
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Enrique Ginzburg
Acute Respiratory Distress Syndrome, COVID-19
A Study of Brexanolone for Acute Respiratory Distress Syndrome (ARDS) Due to Coronavirus Disease 2019 (COVID-19)
The purpose of this study was to evaluate the efficacy and safety of brexanolone in participants on ventilator support for acute respiratory distress syndrome (ARDS) due to COVID-19.
- Trial name
- NCT04537806
- Testing
- Brexanolone
- Where
- 9 sites in United States
- Volunteers
- 29 people
- Sponsor
- Sage Therapeutics
COVID-19 Disease
Study of LAU-7b for the Treatment of Coronavirus Disease 2019 (COVID-19) Disease in Adults
A randomized, double-blind, placebo-controlled Phase 2/3 Study of LAU-7b against confirmed COVID-19 Disease in hospitalized patients at a higher risk of complications.
- Trial name
- RESOLUTION (NCT04417257)
- Testing
- LAU-7b
- Where
- 29 sites in United States, Canada
- Volunteers
- 351 people
- Sponsor
- Laurent Pharmaceuticals Inc.
Healthy Participants
A Study to Learn About the Study Medicine PF-07321332 and Ritonavir in Adult Healthy Chinese Participants.
The purpose of this Phase 1 clinical trial is to help us understand how the drug is changed and eliminated from your body after you take it, the safety, and the the extent to which dise effects can be tolerated of PF-07321332…
- Trial name
- NCT05339334
- Testing
- PF-07321332/ritonavir
- Where
- China
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Pfizer
Covid19 and Mortality
Factors Affecting Mortality in Critical Patients Admitted to Intensive Care Unit Due to Coronavirus Disease 2019
Gazi Yasargil Training and Research Hospital, located in Diyarbakır province in southeastern Turkey, was designed as a pandemic hospital from the beginning of the coronavirus disease-2019 (COVID-19) outbreak.
- Trial name
- NCT04659876
- Testing
- clinical features and laboratory values
- Where
- Turkey (Türkiye)
- Volunteers
- 445 people
- Sponsor
- Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital
COVID-19
Study in Participants With Early Stage Coronavirus Disease 2019 (COVID-19) to Evaluate the Safety, Efficacy, and Pharmacokinetics of Remdesivir Administered by Inhalation
The primary objective of this study is to characterize the impact of inhaled remdesivir (RDV) on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral load in participants with early stage coronavirus disease 2019…
- Trial name
- NCT04539262
- Testing
- Remdesivir (RDV)
- Where
- 28 sites in United States
- Volunteers
- 156 people
- Sponsor
- Gilead Sciences
Covid19
Study to Evaluate the Safety, Tolerability, and Efficacy of BGE-175 in Hospitalized Adults With Coronavirus Disease 2019 (COVID-19) That Are Not in Respiratory Failure
The primary objectives of this study are to evaluate the safety, tolerability, and efficacy of BGE-175 in participants ≥ 50 years of age hospitalized with documented COVID-19.
- Trial name
- NCT04705597
- Testing
- BGE-175
- Where
- 26 sites in United States, Argentina and 1 more
- Volunteers
- 194 people
- Sponsor
- BioAge Labs, Inc.
Coronavirus Disease 2019
Evaluate the Efficacy & Safety of Leronlimab in Patients With Severe or Critical COVID-19
The purpose of this study was assess the safety and efficacy of leronlimab (PRO 140) administered as weekly subcutaneous injection in subjects with severe or critical COVID-19 disease.
- Trial name
- NCT04347239
- Testing
- Leronlimab (700mg)
- Where
- 18 sites in United States
- Volunteers
- 484 people
- Sponsor
- CytoDyn, Inc.
Covid-19
Treatment of Severe Coronavirus Disease 2019 (COVID-19) With Convalescent Plasma
The investigators hypothesize that use of convalescent plasma donated from individuals recovered from Coronavirus Disease 2019 (COVID-19) will help expedite recovery of individuals with active, severe COVID-19 infection.
- Trial name
- Inova-CCP (NCT04502472)
- Testing
- Convalescent plasma transfusion
- Where
- United States
- Volunteers
- 109 people
- Sponsor
- Inova Health Care Services
Covid19
Intramuscular and Intravenous VIR-7831 (Sotrovimab) for Mild/Moderate COVID-19.
The COMET-TAIL main study evaluated efficacy, safety, and tolerability of IM sotrovimab versus IV sotrovimab in high-risk patients for the treatment of mild/moderate COVID-19.
- Trial name
- NCT04913675
- Testing
- sotrovimab
- Where
- 50 sites in United States, France and 1 more
- Volunteers
- 1,065 people
- Sponsor
- Vir Biotechnology, Inc.
Covid19
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Neutralizing Antibody BGB-DXP593 in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)
The primary objective of this study is to evaluate the efficacy of BGB-DXP593 administered intravenously as a single dose in participants with mild to moderate COVID-19
- Trial name
- NCT04551898
- Testing
- BGB-DXP593
- Where
- 18 sites in United States, Brazil and 2 more
- Volunteers
- 181 people
- Sponsor
- BeiGene
Covid19
To Evaluate the Safety and Efficacy of TQ Formula in Covid-19 Participants
This is a randomized (1:1), double-blind, placebo-controlled phase 2 study to assess safety and efficacy of Total TQ Formula (3 g daily dose of Nigella Sativa Oil) capsules versus placebo in treating patients who have tested…
- Trial name
- BOSS (NCT04914377)
- Testing
- TQ Formula/Tab
- Where
- 3 sites in United States
- Volunteers
- 55 people
- Sponsor
- Novatek Pharmaceuticals
Coronavirus Disease 2019 (COVID-19), Acute Lung Injury
Dociparstat for the Treatment of Severe COVID-19 in Adults at High Risk of Respiratory Failure
This was a randomized, double-blind, placebo-controlled Phase 2/3 study to evaluate the safety and efficacy of dociparstat sodium in adult patients with acute lung injury (ALI) due to Coronavirus Disease 2019 (COVID-19).
- Conditions
- Coronavirus Disease 2019 (COVID-19), Acute Lung Injury, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
- Trial name
- NCT04389840
- Testing
- Dociparstat sodium
- Where
- 12 sites in United States
- Volunteers
- 27 people
- Sponsor
- Jazz Pharmaceuticals
Chronic Kidney Diseases, COVID-19
COVID-19 Vaccine Boosters in Patients With CKD
This study is a 12-month, four-arm parallel-group randomized control trial of Pfizer-BioNTech versus MODERNA COVID-19 (Corona Virus disease 2019)vaccine boosters in chronic kidney disease and dialysis patients with poor humoral…
- Trial name
- BOOST KIDNEY (NCT05022329)
- Testing
- Pfizer-BioNTech COVID-19 Vaccine, MODERNA SARS-CoV-2 Vaccine
- Where
- 3 sites in Canada
- Volunteers
- 273 people
- Sponsor
- Sunnybrook Health Sciences Centre
Covid19
Hydroxychloroquine as Chemoprevention for COVID-19 for High Risk Healthcare Workers
The study proposes to conduct an open-label Phase II trial to evaluate the feasibility, safety and early efficacy of hydroxychloroquine (HCQ) administration in reduction of transmission of severe acute respiratory syndrome…
- Trial name
- NCT04345653
- Testing
- Hydroxychloroquine Sulfate (HCQ)
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Hackensack Meridian Health